Stock SRZN SURROZEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Surrozen, Inc.

Equities

SRZN

US86889P2083

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
8.97 USD -0.44% Intraday chart for Surrozen, Inc. -4.17% -4.57%
Apr. 10 Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 08 Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing MT

Business Summary

Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body's response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.

Number of employees: 42

Managers

Managers TitleAgeSince
Craig Parker CEO
 Chief Executive Officer 63 18-02-28
Charles Williams DFI
 Director of Finance/CFO 46 20-10-31

Members of the board

Members of the board TitleAgeSince
Craig Parker CEO
 Chief Executive Officer 63 18-02-28
Eric Bjerkholt BRD
 Director/Board Member 64 23-04-04
Mace Rothenberg BRD
 Director/Board Member 67 21-03-31
Christopher Chai BRD
 Director/Board Member 58 21-03-31
Timothy Kutzkey BRD
 Director/Board Member 49 16-03-31
Anna Berkenblit BRD
 Director/Board Member 54 18-07-31
Mary Haak-Frendscho BRD
 Director/Board Member 67 21-02-28
David Woodhouse CHM
 Chairman 54 20-08-31
Shao Lee Lin BRD
 Director/Board Member 57 20-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,198,786 3,015,467 ( 94.27 %) 0 94.27 %

Shareholders

NameEquities%Valuation
The Column Group LLC
39.74 %
810,089 39.74 % 13 M $
RA Capital Management LP
15.88 %
323,662 15.88 % 5 M $
Goldman Sachs & Co. LLC (Private Banking)
8.471 %
172,666 8.471 % 3 M $
Euclidean Capital LLC
4.302 %
87,696 4.302 % 1 M $
Stonepine Capital Management LLC
3.164 %
64,500 3.164 % 1 M $
BlackRock Institutional Trust Co. NA
2.870 %
58,494 2.870 % 918 941 $
ArrowMark Colorado Holdings LLC
2.704 %
55,123 2.704 % 865 982 $
Board of Trustees of the Leland Stanford Junior University
2.558 %
52,131 2.558 % 818 978 $
The Trustees of Columbia University in The City of New York
2.351 %
47,930 2.351 % 752 980 $
Morgan Stanley Capital Services LLC
1.727 %
35,211 1.727 % 553 165 $
NameEquities%Valuation
Baker Bros. Advisors LP
-
833,333 - 25 000 $
LMR Partners LLP
-
648,285 - 19 449 $
Bridger Management LLC
-
466,666 - 14 000 $
Altitude Crest Partners, Inc.
-
384,573 - 11 537 $
Euclidean Capital LLC
-
170,833 - 5 125 $
Deerfield Management Co. LP (Private Equity)
-
166,666 - 5 000 $
Perceptive Advisors LLC
-
166,666 - 5 000 $
ArrowMark Colorado Holdings LLC
-
108,333 - 3 250 $
Samsara Biocapital LLC
-
99,999 - 3 000 $
Altium Capital Management LP
-
82,233 - 2 467 $

Company contact information

Surrozen, Inc.

171 Oyster Point Boulevard Suite 400

94080, South San Francisco

+

http://www.surrozen.com
address Surrozen, Inc.(SRZN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.97 USD
Average target price
33 USD
Spread / Average Target
+267.89%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SURROZEN, INC. Stock Surrozen, Inc.
-4.57% 28.82M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+4.09% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+47.81% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+9.45% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.32% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.87% 18.47B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.70% 12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.28% 12.33B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.78% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SRZN Stock
  4. Company Surrozen, Inc.